Registration Now Open for Webcast on Corticosteroids in Septic Shock

​Registration is now open for Use of Corticosteroids in Septic Shock, the latest webcast from the Society of Critical Care Medicine’s (SCCM) Controversies in Critical Care series. Treating critically ill patients can be further complicated by a diagnosis of septic shock; the treatment options are varied and debatable. This webcast will discuss the rationale for use or non-use of corticosteroids in critically ill patients with septic shock. Djilalli Annane, MD, and Greet Van den Berghe, MD, PhD, will highlight the controversies surrounding the use of low-dose corticosteroids and its association with clinical outcomes.

Learning Objectives

  • List the rationales for the use of low dose steroids in septic shock
  • Explain the controversies surrounding steroid use and clinical outcomes
  • Describe the context in which steroids should be used (i.e. dose, duration, severe sepsis vs. septic shock)
  • Outline the end points for use of steroids (i.e., mortality vs. shock reversal)
  • Categorize the adverse effects expected for steroid use in the critically ill
  • Review the 2012 SCCM septic shock guidelines regarding recommendations for steroid use.

This webcast will take place on Tuesday, June 24, 2014, at 1:00 p.m. Central Time and participants will receive 1 hour of continuing education credit.

Register online today using your Customer ID and password. The registration fee for this 60-minute webcast is $30 for SCCM members and $40 for nonmembers. For institutions seeking unlimited participation, a $200 group rate is available. Please contact SCCM Customer Service at +1 847 827-6888 to inquire.

The Controversies in Critical Care webcast series is a joint project of the SCCM Scientific Review Committee and the American College of Critical Care Medicine's Ethics Committee. This series is intended to provide insight into topics in critical care medicine for which there is no clear consensus or unequivocal evidence for guiding practice decisions.